RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas
RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas
Not yet recruiting · NCT07563543 · Registry updated 2026-05-04Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Not yet recruiting | Early phase 1 | 2026-05-04 | NCT07563543 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| The First Affiliated Hospital with Nanjing Medical University | 319 |
0 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| No products are listed yet. | |||